Medication Abortion Dominates US Landscape Amid Escalating Legal Challenges

The landscape of reproductive healthcare in the United States has undergone a fundamental structural shift, with medication abortion—specifically the two-drug regimen of mifepristone and misoprostol—now accounting for more than 60% of all abortions nationwide. This transition from clinic-based surgical procedures to pharmacy-dispensed or mail-order medications represents a significant decentralization of care, presenting both a solution to access barriers and a new, complex frontier for legal and regulatory technology. As the method gains ground, the regulatory battleground has shifted from the steps of clinics to the administrative halls of the FDA and the digital infrastructure of telehealth platforms.

The primary catalyst for this growth has been the incremental deregulation by the Food and Drug Administration (FDA). In 2021, the agency permanently removed the requirement that mifepristone be dispensed in person, allowing for telehealth consultations and mail-order delivery. This regulatory pivot transformed the logistics of reproductive care, enabling providers in "shield law" states—such as Massachusetts, New York, and Washington—to prescribe and mail medications to patients in jurisdictions where abortion is restricted or banned. For RegTech firms and legal departments, this has created a high-stakes environment of "conflict of laws," where state-level protections clash directly with federal mandates and the restrictive statutes of neighboring states.

“

FDA, sought to roll back the FDA’s approval of mifepristone entirely.

Opponents of medication abortion have responded with a multi-pronged legal strategy targeting the very foundations of the FDA’s authority. The most prominent challenge, Alliance for Hippocratic Medicine v. FDA, sought to roll back the FDA’s approval of mifepristone entirely. While the Supreme Court recently preserved access based on a lack of standing for the plaintiffs, the underlying legal theories regarding the "arbitrary and capricious" nature of the FDA’s 2016 and 2021 regulatory changes remain a persistent threat. For the pharmaceutical industry, this case signals a potential shift in judicial deference to agency expertise, suggesting that long-standing drug approvals could be vulnerable to litigation decades after the fact.

Furthermore, the "sleeping giant" of this regulatory conflict is the Comstock Act of 1873. This 19th-century anti-obscenity law, which prohibits the mailing of "obscene, lewd, or lascivious" materials—including items intended for producing abortion—is being revitalized by legal strategists. If interpreted strictly by a future administration or a conservative court, the Comstock Act could effectively bypass the FDA’s regulatory framework, creating a de facto national ban on the shipment of abortion medications. This creates a precarious compliance environment for common carriers like UPS and FedEx, as well as retail giants like CVS and Walgreens, which began dispensing mifepristone in select states in early 2024.